טוען...
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
AIM: The aim of the present study was to estimate the annual per-patient cost of treatment with adalimumab, etanercept, infliximab, and ustekinumab by response status for new and existing patients with moderate to severe psoriasis in Greece. METHODS: An economic analysis was developed from a nationa...
שמור ב:
| הוצא לאור ב: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4293299/ https://ncbi.nlm.nih.gov/pubmed/25609988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S75263 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|